Armistice Capital
MBRX icon

Armistice Capital’s Moleculin Biotech MBRX Stock Holding History

Armistice Capital’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,500
Closed -$1.22M – 242
2025
Q1 		$1.22M Buy
2,500
+1,865
+294% +$1.25M 0.02% 159
2024
Q4 		$540K Buy
635
+55
+9% +$66.6K 0.01% 177
2024
Q3 		$824K Buy
580
+268
+86% +$386K 0.01% 176
2024
Q2 		$549K Buy
312
+15
+5% +$34.6K 0.01% 176
2024
Q1 		$878K Sell
297
-131
-31% -$559K 0.01% 169
2023
Q4 		$2.75M Buy
+428
New +$1.78M 0.04% 142
2019
Q2 		– Sell
-5
Closed -$179K – 73
2019
Q1 		$179K Buy
+5
New +$298K 0.01% 69

Other funds holding MBRX

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Virtu Financial
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Armistice Capital's MBRX Position: Q2 2025 in Review

Armistice Capital sold out of Moleculin Biotech (MBRX) in Q2 2025, closing a stake of 2,500 shares — an estimated $1.22M sold.

Armistice Capital first reported a position in MBRX in Q1 2019 and held it in 7 quarters. The position peaked at $2.75M in Q4 2023. 17 funds tracked by Wall St. Rank hold MBRX as of Q2 2025.

  • Armistice Capital reported no remaining Moleculin Biotech position as of Q2 2025 after selling out during the quarter.
  • Armistice Capital sold 2,500 Moleculin Biotech shares in Q2 2025, an estimated $1.22M.
  • Armistice Capital first reported a position in Moleculin Biotech in Q1 2019 and held it in 7 quarters.
  • Armistice Capital's Moleculin Biotech position peaked at $2.75M in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.